Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Net Cash Flow for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 107.15% year-over-year to $1.1 million; the TTM value through Dec 2025 reached -$13.4 million, down 14.82%, while the annual FY2025 figure was -$13.4 million, 0.84% down from the prior year.
  • Net Cash Flow hit $1.1 million in Q4 2025 for Artiva Biotherapeutics, up from -$3.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $21.6 million in Q3 2024 and bottomed at -$15.6 million in Q4 2024.
  • Average Net Cash Flow over 3 years is -$2.5 million, with a median of -$4.1 million recorded in 2024.
  • On a YoY basis, Net Cash Flow climbed as much as 107.15% in 2025 and fell as far as 113.68% in 2025.
  • Artiva Biotherapeutics' Net Cash Flow stood at -$12.4 million in 2023, then dropped by 26.37% to -$15.6 million in 2024, then soared by 107.15% to $1.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $1.1 million, -$3.0 million, and -$2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.